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Abstract
Hematopoietic cells from the malignant clone in chronic my-
elogenous leukemia (CML) maintain and expand a prolifera-
tive advantage over normal hematopoietic cells within the bone
marrow. This advantage is often ameliorated or reversed in vivo
by IFNa. Based upon earlier studies suggesting decreased adhe-
siveness ofCML progenitor cells, we asked whetherCML pro-
genitor cells are deficient in their expression of the cytoadhe-
sion molecule lymphocyte function antigen-3 (LFA-3, CD58)
which is normally expressed on hematopoietic progenitors.
Progenitor cells from untreated CML patients showed greatly
reduced or absent LFA-3 expression, whereas progenitors from
patients treated with IFNa in vivo or in vitro expressed surface
LFA-3 at more normal levels. LFA-3-deficient CML progeni-
tor cells were unable to stimulate normal regulatory prolifera-
tive responses in autologous T cells. We hypothesize that
IFNa-sensitive LFA-3 deficiency reflects a cell surface cytoad-
hesion defect which may help explain adhesive abnormalities of
CML progenitor cells in vitro and clonal proliferation in vivo.
(J. Clin. Invest. 1991. 88:2131-2136.) Key words: adhesion-
clonal expansion * stem cell
Introduction
The (9;22) Philadelphia translocation of chronic myelogenous
leukemia (CML)' was the first described nonrandom transloca-
tion in malignancy, and has now been molecularly identified
with the structurally and functionally abnormal chimeric pro-
tooncogene bcr-abl (1-5). CML evolves clinically to more ad-
vanced stages through the sequential acquisition of additional
cytogenetic abnormalities, a pattern which has recently been
demonstrated in common solid tumors as well (6-8).
Despite these important advances in our understanding of
CML, the process by which the affected malignant clone main-
tains its proliferative advantage in vivo remains unknown, de-
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1. Abbreviations used in this paper: APLR, autologous proliferative
response; BFU-E, erythroid burst forming units; CML, chronic myelog-
enous leukemia; IMDM, Iscove's modified Dulbecco's medium; LFA-
3, lymphocyte function antigen-3; PI, phosphatidyl-inositol; PNH, par-
oxysmal nocturnal hemoglobinuria.
spite extensive in vitro investigation. When grown in short-
term colony forming assays, CML progenitor cells appear to
display the same dependence on hematopoietic growth factors
as do normal progenitors. In long-term liquid cultures, progen-
itors arising from the CML clone survive less well than do
normal progenitors, and actually disappear over time leaving
behind only normal cells (9). Finally, while in vivo IFN,, treat-
ment ameliorates or totally reverses the proliferative advantage
ofthe CML clone, with 15-25% ofcases experiencing complete
cytogenetic remission (10), no in vitro assay to date has identi-
fied a selective effect of IFNa on CML versus normal hemato-
poietic cells.
Several lines of circumstantial evidence suggests that CML
progenitor cells are deficient in their expression of cell surface
cytoadhesion molecules. First, Gordon et al. found that CML
progenitor cells adhered poorly to bone marrow stromal mono-
layers in vitro, and more recently have suggested that normal
progenitor cell stromal adhesion is mediated through a phos-
phatidyl-inositol(PI)-linked surface receptor (1 1, 12). Next, the
cytochemical hallmark ofCML is decreased expression of the
PI-linked ectoenzyme leukocyte alkaline phosphatase (13). Fi-
nally, lymphocyte function associated antigen three (LFA-3,
CD58) whose cell surface expression can be linked through PI,
has been found to be underexpressed in EBV-transformed cell
lines, leading to their escape from immune surveillance and
suppression by autoreactive T lymphocytes (14). Taken to-
gether, these observations suggest that deficient expression of
critical progenitor cell cytoadhesion molecules, including those
which include PI-linked isoforms such as LFA-3, might contrib-
ute to the pathophysiologic clonal expansion ofthe CML clone
in vivo.
We therefore asked whether CML progenitor cells bear cell
surface LFA-3 as detectable in a solid phase immunoabsorp-
tion assay. Our results demonstrate that CML progenitor cells
are deficient in their expression of LFA-3, and suggest that
IFNa treatment in vivo and in vitro restores deficient LFA-3
expression. In addition, the data indicate that CML cells in-
deed fail to stimulate autoimmunoregulatory T cell responses
characteristic of normal bone marrow progenitor cells.
Materials
Bone marrow mononuclear cells. Clinical samples used in this study
were obtained coincident to routine diagnostic procedures used to eval-
uate CML patients at the M.D. Anderson Cancer Center, under a pro-
tocol approved by the M.D. Anderson Cancer Center Human Subjects
Committee. Normal bone marrow was aspirated under local anesthesia
from volunteers following informed consent, under a protocol ap-
proved by the University of Michigan Institutional Review Board.
Mononuclear cells were prepared by centrifugation over Ficoll-Hypa-
gue (Sigma Chemical Co., St. Louis, MO), 1.077. After three washes in
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Iscove's modified Dulbecco's medium (IMDM) supplemented with 2%
FCS (Hyclone Laboratories Inc., Logan, UT), adherent cells were re-
moved by overnight incubation at 106 cells/ml in IMDM + 20% FCS
over 100-mm plastic dishes (Corning Glass Inc., Corning, NY).
Separation of LFA-3(CD58)+ and - cells. Nonadherent bone
marrow mononuclear cells were separated into LFA-3(CD58)+ and -
fractions by panning (15, 16). Briefly, the cells were suspended in
IMDM plus 5% FCS in the presence of mouse anti-human LFA-3
(TS2.9 ascites, generously provided by Drs. Carol Clayberger and Alan
Krensky, Stanford University, Palo Alto, CA) for 1 h at 4VC, washed,
resuspended in PBS plus 5% FCS, and incubated at 4VC over 100-mm
plastic tissue culture dishes coated with 5 ml rabbit anti-mouse Ig (100
,gg/ml; Zymed Labs, Inc., South San Francisco, CA). After 1 h, the
plates were gently tipped and nonadherent, LFA-3- cells removed by
aspiration. After once gently rinsing the plates, 5 ml IMDM plus 5%
FCS was added and the adherent cells incubated for 30 min at 370C
under 5% CO2. The previously adherent, LFA-3' cells were then recov-
ered by aspiration and the use ofa rubber policeman. Analogous proce-
dures were followed to isolate + and - cells for other antigens, using
acHLA-DR (300 Ag/l06 cells; Becton Dickinson and Co., Cockeysville,
MD), aHLA-DQ (aLeu-10, 500 yg/l06 cells; Becton Dickinson),
aCD15(aLeu-M I, 300 ,tg/ 106 cells; Becton Dickinson), aglycophorin
A(4F7, 100 ,Ag/106 cells, generously provided by Dr. William Bigbee,
Lawrence Livermore Laboratories), aLFA-la chain/CD1 la and
aLFA-lb chain/CD 1 8 (1/200 hybridoma supernatant, both gener-
ously provided by Drs. Carol Clayberger and Krensky).
Methykcellulose cultures. Each fraction was cultured in 0.9% meth-
ylcellulose supplemented with 10% deionized BSA and 30% FCS in the
presence ofinterleukin 3 (10 ng/ml, generously provided by Dr. Steven
Clark, Genetics Institute, Cambridge, MA) and erythropoietin (2 U/
ml, Amgen Biologicals, Thousand Oaks, CA), and erythroid (burst
forming unit-erythroid-derived), myeloid (granulocyte-macrophage
colony forming unit-derived), and multilineage (granulocyte-ery-
throid-macrophage-megokaryocyte colony forming unit-derived) colo-
nies enumerated on day 17.
Interferon treatment in vitro. Nonadherent CML bone marrow
mononuclear cells were incubated at 106 cells/ml in IMDM plus 20%
FCS supplemented with 0-200 U/ml IFNG (Schering Corp., Kenil-
worth, NJ) for 24 h at 37°C under 5% CO2. Aliquots were withdrawn at
0, 4, 12, and 24 h, the cells separated into LFA-3+and LFA-3- fractions
by panning, and progenitor cells enumerated by methylcellulose cul-
ture in the presence of IL-3 plus Epo. The data are presented as progen-
itor cells per 105 cell before fractionation.
Detection of the bcr-abl rearrangement by polymerase chain reac-
tion (PCR) in individual colonies. Ethidium bromide-stained Nusieve/
agarose (3%/1%) gels of PCR products, obtained from reverse-tran-
scribed mRNA from myeloid colonies plucked from methylcellulose
cultures. Methods: Nonadherent bone marrow cells from a CML pa-
tient whose untreated progenitor cells were 92% LFA-3- were incu-
bated with IFN,, for 24 h, then fractionated into LFA-3- and LFA-3+
fractions by panning, and each fraction cultured for 14 d in methylcel-
lulose. 96% of the colonies were detected in the LFA-3+ fraction. 12
well separated LFA-3+ colonies were plucked with a 10 yd glass pipette,
each colony was washed in PBS, and RNA was extracted essentially as
described (17). Methylcellulose from adjacent portions of the culture
plates was plucked and processed in parallel, and RNA from the K562
cell line and normal human bone marrow were processed as positive
controls as well. cDNA was synthesized with reverse transcriptase using
a specific primer present in both normal and rearranged bcr messages.
The cDNA was divided in halffor assay ofboth normal abland bcr abl.
First round PCR primers and nested primers for bcr-abl were as de-
scribed (I17), and nested primers for second round normal abl amplifi-
cation were GCTCCGGCCCGATCGTTCGCTTGGCGCAAA for
exon la, GACCAAAGAAGGCCAAGCTTGCCTGCCCTG for exon
lb, and CTCAGACCCTGAGGCTCAAAGTCAGATGCT for 3' abl
sequence. The polymerase chain reaction (I18, 19) was performed with
Taq polymerase by denaturation at 94°C for 1 min and primer exten-
sion at 720C for 2 min, for 35 rounds with no annealing step. In 11/12
samples normal abl as well as bcr-abl could be detected on an ethidium
bromide-stained gel. DNA from all 12 colonies was transferred after
electrophoresis to Genescreen and hybridized with end-labelled inter-
nal 3' abl oligonucleotide, at 50'C by the method of Church and Gil-
bert (20), to confirm the identity ofthe visualized PCR products and to
score samples in which the PCR product could not be visualized di-
rectly on a gel.
Stimulation ofautologous proliferating T cells in response to pro-
genitors (APLR). Highly enriched CML or normal bone marrow pro-
genitor cells were prepared by removing contaminating nonprogenitor
cells (T cells, B cells, NK cells, myeloid and erythroid precursors) by
negative immunoselection on plastic dishes (15, 16), and irradiated
with 20 Gy. I05 autologous CD5' T cells were incubated with I05
irradiated progenitor cells for 8 d, the cultures pulsed with 3HTdR for
16 h, and the cells were harvested. T cell proliferation was measured by
the stimulation index, i.e., the ratio of 3H incorporation into T cells
stimulated with progenitor cells, versus 3H incorporation into unstimu-
lated T cells (21).
Results
CML progenitor cells are deficient in the expression ofcell sur-
face LFA-3 (CD58). Bone marrow mononuclear cells from a
normal donor, and from a patient with newly diagnosed, un-
treated CML, were labelled with murine anti-human LFA-3,
or anti-human LFA- I or anti-HLA-DR, and separated by pan-
ning into antibody positive and negative cell fractions (15-16).
Each fraction was then cultured in methylcellulose, and pro-
genitor cells measured by enumeration of unilineage and mul-
tilineage hematopoietic colonies at 17 d. The normal bone
marrow progenitor cells were uniformly LFA-3', with 86/86
erythroid burst forming units (BFU-E), 120/122 granulocyte-
macrophage colony forming units (CFU-GM), and 14/14 mul-
tilineage colony forming cells (CFU-GEMM) partitioning into
the LFA-3' fraction. In contrast, > 95% ofthe progenitor cells
from the CML bone marrow sample partitioned into the LFA-
3- fraction (Table I). Similar results were obtained in 10 nor-
mal controls, whose progenitor cells were nearly all LFA-3' in
this assay, and in 17 additional patients with untreated stable
phase CML, most or all ofwhose progenitor cells were LFA-3-.
This underexpression of cell surface LFA-3 appeared not to be
Table L Fractionation ofNormal and CML Progenitor Cells
Via the Expression ofCell Surface LFA-3
Colonies per IO' Cells*
Bone
Sample marrow fraction BFJ-E CFU-GM CFU-GEMM
Normal BM LFA-3+ 86 120 14
LFA-3- 0 2 0
Untreated CML LFA-3+ 12 14 0
LFA-3- 93 81 7
* Nonadherent bone marrow mononuclear cells were separated into
LFA-3+ and - fractions by panning. The + and - fractions were
cultured in 0.9% methylcellulose, and erythroid (burst forming
unit-erythroid-derived), myeloid (granulocyte-macrophage colony
forming unit-derived), and multilineage (granulocyte-erythroid-mac-
rophage-megokaryocyte colony forming unit-derived) colonies enu-
merated on day 17. The data are presented based on 105 cells before
LFA-3 fractionation.
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caused by the proliferative bone marrow state of these patients
per se, as progenitor cells from three patients with nonleuke-
mic, reactive leukocytosis were 100% LFA-3+ (Fig. 1). This
disparity between CML and normal progenitor cell surface an-
tigen expression was not found for several other cell surface
proteins expressed on bone marrow cells, including LFA- 1 and
HLA-DR (Table II). Untreated stable phase CML hematopoi-
etic progenitor cells, therefore, are relatively LFA-3 deficient
compared with normal nonleukemic progenitor cells.
Progenitor cellsfrom CML patients treated with interferon
a express partially orfully normalized LFA-3 in vivo. Since the
treatment ofCML with IFNa results in amelioration or reversal
ofthe proliferative advantage ofthe CML clone in vivo (12), we
next examined bone marrow samples from CML patients be-
ing treated with IFNa. In contrast to the CML patients before
treatment, IFNa-treated CML patients displayed partially or
completely restored surface LFA-3 expression, with 30-100%
of progenitor cells recovered in the LFA-3+ fraction (Fig. 1,
final column). Individual CML patients were then studied both
before and after treatment with IFNa, to determine if progeni-
tor cell surface LFA-3 expression could be amplified over time
following treatment. Progenitor cell surface LFA-3 expression
was increased in each ofthree cases studied, to variable extents,
after 3-6 mo of therapy (Fig. 2). These data suggested that
treatment with IFNa might partially or completely reverse
LFA-3 deficiency on the CML progenitor cells.
Interferon a reverses CML progenitor cell LFA-3 deficiency
in vitro. These marrow samples from IFNa-treated CML pa-
tients, however, might have contained increased and variable
percentages of normal, nonleukemic progenitor cells. There-
fore, the observed restoration of progenitor cell LFA-3 expres-
sion might have been simply due to sampling oflarge numbers
ofnonleukemic progenitors that had been selected in vivo over
months of IFNa therapy. We therefore asked whether IFNa
Table II. Expression of Cell Surface Antigens on Normal and
CML Progenitor Cells
% + Bone marrow progenitors
Cell surface
antigen (antibody) CML BM Normal BM
n=7 n=10
Gpn A 0±0* 0±0
HLA-DR 88±7 95±4
HLA-DQ 9±6 4±3
CD34 96±3 98±2
CD15 5±5 7±4
LFA-la/CDl la 11±6 9±4
LFA-l,/CD18 6±3 7±3
LFA-3/CD58 21±7 93±3
* Percentage of total BFU-E + CFU-GM + CFU-GEMM recovered
in the adherent fraction after panning as described in Table I, using
the primary murine monoclonal antibodies to the specified epitopes.
The data presented are means ± SD for analyses from 7 CML and
10 normal bone marrow samples.
could reverse deficient LFA-3 expression in vitro, before clonal
selection could occur. Progenitor cells from an untreated CML
patient were incubated in 200 U/ml IFN., the peak plasma
dose achieved after subcutaneous administration in vivo, for
up to 24 h, fractionated into LFA-3+ and LFA-3- cells by pan-
ning, and plated in methylcellulose. Whereas before IFNa,
treatment, 80% ofBFU-E, 83% ofCFU-GM, and 90% ofCFU-
GEMM were LFA-3-, after 24 h in vitro IFNa incubation 75%
of BFU-E, 68% of CFU-GM, and 80% of CFU-GEMM were
LFA-3+ (Fig. 3). Moreover, while the absolute densities of
so
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Figure 1. LFA-3 expression on CML progenitor cells. Nonadherent
bone marrow mononuclear cells from 10 normal donors (A), CML
patients not treated with IFNa, (B), IFN.-treated CML patients (C),
or patients with nonleukemic elevations in neutrophil counts (D) were
separated into LFA-3+ and LFA-3- fractions by panning. Each frac-
tion was cultured in methylcellulose, and erythroid (burst forming
unit-erythroid-derived), myeloid (granulocyte-macrophage colony
forming unit-derived) and multilineage (granulocyte-erythroid-mac-
rophage-megokaryocyte colony forming unit-derived) colonies enu-
merated on day 17. Data are presented as the percentage of total
(BFU-E + CFU-GM + CFU-GEMM) present in the LFA-3+ fraction.
Progenitor cell surface LFA-3 was detected in this assay on 93±3%
of normal progenitors.
20
0 3
PRE TX
MONTHS ON IFN a
Figure 2. Response of progenitor cell LFA-3 expression to IFNa
treatment in vivo. Bone marrow samples were obtained from three
patients both before and after several months of treatment with IFN,
in vivo, and progenitor cells were analyzed for their expression of
LFA-3 as described in Methods and in Fig. 1.
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LFA-3- progenitor cells did fall during this incubation, the
concentration of LFA-3' progenitors rose, suggesting that in-
creased LFA-3 expression was caused not simply by rapid se-
lective in vitro toxicity to CML progenitors, but by induction
of surface LFA-3 expression on previously LFA-3- progenitor
cells. This LFA-3 inductive effect was seen at IFNa concentra-
tions from 50-1,000 U/ml, which encompasses peak and
trough levels obtained during in vivo patient treatment with
IFNa (Fig. 4). Similar results were obtained in six additional
untreated CML patients, with progenitor cell LFA-3 expres-
sion increased from 0-13% to 31-96% (Table III).
Despite these kinetic and quantitative data, we wished to
definitively exclude the possibility that IFNa treatment in vitro
was selecting for the growth of normal over leukemic progeni-
tor cells in the LFA-3' fraction. In these studies, hematopoietic
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Figure 4. Pharmacologic doses of IFN. induces LFA-3 expression on
CML progenitors in vitro: IFNa dose response. Nonadherent bone
marrow mononuclear cells were cultured at 106 cells/ml in the pres-
ence of 0, 50 U, 200 U, and 1,000 U/ml IFNa for 24 h. The cells
were then fractionated into LFA-3' and LFA-3- cells by panning, and
the + and - fractions cultured in the methylcellulose with IL-3 and
Epo. The data are presented as percent (BFU-E + CFU-GM + CFU-
GEMM) in the LFA-3' fraction.
Figure 3. Pharmacologic doses ofIFNa induces LFA-3
expression on CML progenitors in vitro: time course.
Nonadherent CML bone marrow mononuclear cells
were incubated at 106 cells/ml in IMDM plus 20%
FCS supplemented with 200 U/ml IFNa for 24 h at
370C under 5% CO2. Aliquots were withdrawn at 0,
4, 12, and 24 h, the cells separated into LFA-3' and
LFA-3- fractions by panning, and progenitor cells
enumerated by methylcellulose culture in the pres-
ence of IL-3 plus Epo. The data are presented as pro-
genitor cells (BFU-E + CFU-GM + CFU-GEMM)
per 10' cells before fractionation; (o), LFA-3- pro-
genitors, (i) LFA-3V progenitors. Unlabelled CML
bone marrow mononuclear cells treated in parallel
with IFNa did not adhere to RAMIg coated plates
(data not shown in figure).
colonies were grown in methylcellulose, individual colonies
were plucked and suspended in PBS, and RNA extracted and
split into two aliquots. Reverse transcriptase polymerase chain
reaction was used to amplify specific message for abl and bcr-
abl from the two aliquots. In this assay, RNA from colonies
containing cells bearing the Ph chromosomal translocation
would contain both abl and bcr-abl mRNAs, while colonies
from normal hematopoietic progenitors would contain only
abl but not bcr-abl mRNAs. The results revealed that RNA
analysis of individual colonies plucked from the LFA-3' frac-
tion following in vitro interferon treatment confirmed that
each colony expressed the characteristic bcr-abl transcript as
well as the normal abl transcript (Fig. 5). Thus the LFA-3'
progenitor cells arising after IFN, treatment in vitro are indeed
leukemic, and therefore reversion of deficient LFA-3 expres-
Table III. Alpha Interferon Induces LFA-3 Expression on CML
Progenitor Cells In Vitro
Percent LFA-3' progenitors*
Patient number Untreated Post-IFN.
1 16 84
2 0 32
3 8 96
4 0 61
5 0 31
6 0 41
7 13 67
* Percent (BFU-E + CFU-GM + CFU-GEMM) in the LFA-3+ frac-
tion, after separation of nonadherent bone marrow mononuclear
cells into LFA-3+ and LFA-3- fractions, as in Table I. Each patient's
bone marrow was studied immediately and after incubation for 24 h
in IMDM plus 20% FCS in the presence of 200 U/ml IFNa. Incuba-
tion for 24 h in IMDM/FCS without IFN. did not increase LFA-3
expression (data not shown in table). Incubation of normal bone
marrow progenitor cells (n = 4) in the presence of 50-200 U/ml IFNU
did not change LFA-3 expression (96±4 pre-IFNa, 95±7 post-IFN.).
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Figure 5. Detection of the bcr-abl rearrangement by PCR in individ-
ual LFA-3' colonies from CML bone marrow cultured with IFNU in
vitro. Ethidium bromide-stained Nusieve/agarose (3%/1%) gels of
PCR products, obtained from reverse transcribed mRNA from my-
eloid colonies plucked from methylcellulose cultures. In 11/12 sam-
ples normal abl as well as bcr-abl could be detected on an ethidium
bromide-stained gel. DNA from all 12 colonies was transferred after
electrophoresis to Genescreen and analyzed for the presence of abl or
bcr-abl transcripts by alkaline Southern hybridization.
sion in vitro parallels the antiproliferative and anticlonal er-
fects of IFN, in vivo.
CML progenitor cells fail to stimulate autologous T cell
proliferation. We have recently demonstrated that a subset of
normal human T cells does proliferate when exposed to cycling
autologous bone marrow progenitor cells, and that these autor-
eactive T cells suppress autologous hematopoiesis. This autolo-
gous proliferative response to progenitors is specific for CD34'
progenitor cells and is completely blocked by either anti-CD2
or anti-LFA-3 antibodies in vitro (21). We therefore asked
whetherCML LFA-3 deficiency was accompanied by failure of
CML progenitor cells to stimulate a T cell APLR. Highly
enriched progenitor cells were prepared from CML patients
and normal donors, irradiated to 20 Gy, and incubated with
autologous CD5+ T cells for 8 d. Whereas progenitor cells from
normal volunteers, and from patients with reactive leukocyto-
sis (leukemoid reactions) stimulated a brisk APLR, untreated
CML patients failed to stimulate any detectable APLR, and
IFNa-treated CML patients stimulated variable APLR re-
sponses (Fig. 6). These data demonstrate that CML progenitor
cells fail to stimulate autoreactive T cells, which was predicted
from their underexpression of cell surface LFA-3.
Discussion
These data indicate that CML progenitor cells are deficient in
their expression of the cell surface cytoadhesion molecule
LFA-3 (CD58). This deficiency appears to be ameliorated in
patients treated with interferon a. Moreover, treatment of
CML bone marrow with IFNa in vitro reverses the LFA-3 de-
fect over the course of24 h, indicating that the effects observed
on patients treated with IFNa are not simply the result ofclonal
selection in vivo.
LFA-3 is an extremely widely expressed cell surface pro-
tein, whose only known function is as the binding ligand for the
T cell surface protein CD2 (22, 23). Its presence is thought to
stabilize the interactions between T cells and their cellular tar-
gets, including antigen presenting cells and virally infected
cells. Deficiency in LFA-3 on EBV-transformed B cell lines
have led to the hypothesis that this deficiency prevents'the nec-
essary T cell binding required for proper immune surveillance
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Figure 6. Irradiated CML progenitor cells fail to stimulate the prolif-
eration,ofautologous T lymphocytes. Highly enriched CML or nor-
mal bone marrow progenitor cells were prepared by removing con-
taminating nonprogenitor cells (T cells, B cells, NK cells, myeloid
and erythroid precursors) by negative immunoselection on plastic
dishes (28), and irradiated with 20 Gy. 10 autologous CD5+ T cells
were incubated with 10' irradiated progenitor cells for 8 d, the cul-
tures pulsed with 3HTdR for 16 h, and the cells were harvested. T cell
proliferation was measured by the stimulation index, i.e., the ratio
of 3H incorporation into T cells stimulated with progenitor cells, ver-
sus 3H incorporation into unstimulated T cells.
in vivo (14). Since LFA-3 is so widely expressed, clonal LFA-3
deficiency could lead to escape from T cell-mediated detection
and regulation ofnonimmune cellular proliferation in a variety
of tissues.
These observations suggest a direct role for interferon",-
reversible LFA-3 deficiency in the pathogenesis of stable phase
CML. Cellular requirements for alloengraftment suggest that
normal human bone marrow contains in the range of 106 stem
cells, and hematopoiesis is maintained by the relatively bal-
anced expression of multiple hematopoietic stem cell clones. If
the cycling progenitor daughter cells of active stem cells are
recognized and modulated by autoreactive T cells, then LFA-3
deficiency might allow CML progenitor cells to escape autore-
cognition and autoregulation. This would exacerbate even a
slight intrinsic proliferative advantage by the CML clone. In
this regard, the failure of highly enriched progenitor cells from
patients withCML to stimulate autologous T cells proliferation
is quite interesting, inasmuch as these autoreactive T cells lo-
cally suppress the differentiation of hematopoietic progenitor
cells (2 1).
In this context it is noteworthy that paroxysmal nocturnal
hemoglobinuria (PNH) cells are deficient in cell surface LFA-3
(24). While PNH and CML have disparate clinical manifesta-
tions, both share the feature that an abnormal clone gradually
becomes overrepresented within the bone marrow. This shared
deficiency suggests that LFA-3 deficiency might lead to overex-
pression of individual hematopoietic cell clones, not to ele-
vated circulating blood cell counts per se. Whether the periph-
eral manifestation ofthe disease includes high white blood cell
and platelet counts as in CML, or low blood cell counts and
unusual hemolytic sensitivity as in PNH would depend on
other pathophysiologic causes distinct from clonal expansion.
Deficient LFA-3 expression might be only one of several
cytoadhesion deficiencies contributing to pathophysiologic
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clonal expansion in CML. Leukocyte alkaline phosphatase and
LFA-3, both deficient in CML cells at different stages ofdiffer-
entiation, are two members of a class of membrane proteins
which may be anchored to the cell surface by linkage to mem-
brane lipids through phosphatidyl inositol (25, 26). Other such
proteins include the adhesion proteins NCAM and decay accel-
erating factor (26). The data ofGordon et al. suggest that primi-
tive hematopoietic cells may adhere to marrow stroma via
phospholipase C-sensitive adhesion molecules (11, 12). While
LFA-3 is expressed on most cells through both PI-linked and
PI-independent forms (26, 27), it is possible that quantitatively
decreased expression may both account for the results ofour in
vitro assays and prevent normal T cell binding in vivo. The
present data support the concept that CML cells may subopti-
mally express critical PI-linked stem cell proteins which medi-
ate adhesion to stromal cells. Deficient expression of such pro-
teins might contribute to the poor survival of CML marrow
cultures in vitro and to failure to regulate CML clonal growth
in hematopoietic niches in vivo. The present data both lend
circumstantial support to such a hypothesis and suggest that
IFNa-responsive CML cells might provide a suitable experi-
mental system to isolate such critical adhesion molecules.
In summary, these data indicate that bone marrow progeni-
tor cells from patients with CML fail to normally express cell
surface LFA-3, and that this deficiency is ameliorated in vivo
and in vitro by IFNa. We hypothesize that this defect may
contribute to the clonal advantage enjoyed by the CML stem
cell progeny in vivo. Similar deficiencies in yet to be isolated
stromal cell cytoadhesion proteins by CML progenitors may
lead to the direct isolation of these molecules.
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